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Introduction: Klippel-Trenaunay Syndrome (KTS) is rare syndrome characterized by a presence of 
capillary and venous malformation, limb overgrowth, with or without lymphatic anomalies1. KTS is 
related to mutations in the PIK3CA gene. Complications of KTS include clotting disorder, bleeding, 
lymphedema, soft tissue infection and pain. Treatment is individualized; it may include endovascular 
or surgical procedures and supportive care (management of coagulopathy, infection, pain). The use 
of mammalian target of rapamycin (mTOR) inhibitor sirolimus shows promising results in complex 
vascular malformations2,3. 
Case report: We present a 45 years old patient, currently living out of Croatia. Vascular malformation 
of the left arm was noticed a few months after his birth. During his childhood an angiography of the 
left arm lead to confirmation of KTS without further specific treatment. During the last 15 years he was 
undergoing regular hematology controls and treatment of consumptive coagulopathy as complication 
of KTS. In 2010 at age 35, he suffered a fracture on the left arm, but he was declared inoperable on basis 
of vascular malformation which extended the healing process. From 2018 further proliferation of vas-
cular malformation was noticed on his left hemithorax. In 2020 he was presented to multidisciplinary 
vascular team, MR angiography was performed Unfortunately, due to extreme extension of vascular 
malformation with soft tissue hypertrophy and osseous deformation the patient is not suitable for any 
surgical or endovascular procedure. We suggested a treatment with sirolimus which is delayed due to 
patient’s temporary relocation. Genetic panel testing covering PIK3CA gene is in progress. 
Conclusion: By presenting this case, our objective is to increase the awareness of KTS, related compli-
cations and the role of sirolimus which can improve the prognosis of vascular anomalies. Additionally, 
we wish to emphasize the importance of multidisciplinary vs specialty focused approach in manage-
ment patients with KTS. 
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